Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03364738 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT03364738 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 22 participants.
The verdict
NCT03364738, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study is open to adults with hypoparathyroidism who complete the SHP634-101 study (PARALLAX Study). The purpose of this study is to see if rhPTH(1-84) is safe and effective in adults with hypoparathyroidism who previously participated in the SHP634-101 study. All participants enrolled in this study will receive rhPTH(1-84) once-daily for 52 weeks via an injection. Patients who complete the SHP634-101 study will have the option to screen for this extension study.
Interventions
- BIOLOGICAL rhPTH(1-84)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2020-04-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03364738
The ClinicalTrials.gov registry entry for NCT03364738 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhPTH(1-84) is the first listed.
NCT03364738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03364738 about?
NCT03364738 is a clinical study titled "Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism". This study is open to adults with hypoparathyroidism who complete the SHP634-101 study (PARALLAX Study). The purpose of this study is to see if rhPTH(1-84) is safe and effective in adults with hypoparathyroidism who previously participated in the SHP634-101 study. All participants enrolled in this s...
What is the current status of trial NCT03364738?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2018-09-26. Estimated completion is 2020-04-14.
What interventions are being tested in trial NCT03364738?
The interventions under investigation include: rhPTH(1-84) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03364738?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.